

Original article

Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain



Antonio Olry de Labry Lima,^{a,b,c,*} Vicente Gimeno Ballester,^d Jesús Francisco Sierra Sánchez,^e Antonio Matas Hoces,^f Julio González-Outón,^g and Emilio Jesús Alegre del Rey^h

^aÁrea de Gestión de Servicios y Profesionales de la Salud, Escuela Andaluza de Salud Pública (EASP), Granada, Spain

^bInstituto de Investigación Biosanitaria (IBS), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain

^cCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain

^dServicio de Farmacia, Hospital Universitario Miguel Servet, Zaragoza, Spain

^eServicio de Farmacia, Hospital de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain

^fCentro Andaluz de Información del Medicamento (CADIME), Campus Universitario de Cartuja, Granada, Spain

^gServicio de Admisión, Documentación e Información Sanitaria, Hospital Universitario Puerto Real, Puerto Real, Cádiz, Spain

^hServicio de Farmacia, Hospital Universitario Puerto Real, Puerto Real, Cádiz, Spain

Article history:

Received 3 November 2017

Accepted 21 February 2018

Available online 22 June 2018

Keywords:

Cardiovascular disease

Secondary prevention

Costs and cost analysis

PCSK9 monoclonal antibodies

ABSTRACT

Introduction and objectives: To analyze the cost-effectiveness ratio and budget impact of treatment with evolocumab (PCSK9 inhibitor) for patients in secondary prevention in the Spanish National Health System.

Methods: A budget impact analysis, decision tree and Markov models were designed under the public health system perspective, based on the only study with morbidity and mortality data (FOURIER). The alternatives compared were evolocumab vs statins, and dual therapy with ezetimibe in 5% of the population. The measure of effectiveness used was the number of cardiovascular events avoided. Univariate and probabilistic sensitivity analyses were performed.

Results: The average annual cost of patients receiving evolocumab was 11 134.78€ and 393.83€ for standard treatment (statins plus ezetimibe). The incremental cost-effectiveness ratio was > 600 000 € per avoided cardiovascular event for both assessed outcomes (first: cardiovascular death, myocardial infarction, stroke, and hospitalization due to unstable angina or coronary revascularization; second: includes the first 3 events). To perform the 10-year Markov model, the average cost of standard treatment was 13 948.45€ vs 471 417.37€ with evolocumab. Treatment with evolocumab for patients with familial hypercholesterolemia would cost between 3 and 6.1 million euros, assuming a difference of 2.5 and 5.1 million euros with the standard treatment (2017). This difference would be between 204.3 and 1364.7 million euros (2021) for those with nonfamilial hypercholesterolemia (secondary prevention).

Conclusions: Treatment with evolocumab is associated with a lower frequency of cardiovascular events, but is inefficient for patients suitable to receive this drug in the Spanish National Health System.

© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Coste-efectividad e impacto presupuestario del tratamiento con evolocumab frente a estatinas y ezetimiba para la hipercolesterolemia en España

RESUMEN

Introducción y objetivos: Analizar la razón de coste-efectividad y el impacto presupuestario del tratamiento con evolocumab (inhibidor de la PCSK9) para pacientes en prevención secundaria en el Sistema Nacional de Salud español.

Métodos: Se realizaron, desde la perspectiva del sistema sanitario público, análisis de impacto presupuestario, modelos de árbol de decisión y Markov, basándose en el único ensayo clínico con datos de morbimortalidad (FOURIER). Las alternativas comparadas fueron evolocumab frente a estatinas y un 5% ezetimiba conjuntamente. La medida de eficacia utilizada fue el número de eventos cardiovasculares evitados. Se realizaron análisis de sensibilidad univariable y probabilístico.

Resultados: El coste sanitario promedio de los pacientes tratados a 26 meses con evolocumab fue de 11.134,78 euros y de 393,83 euros con el estándar (estatinas + ezetimiba). El coste-efectividad incremental superó los 600.000 euros por evento cardiovascular evitado en las 2 variables (primera: muerte cardiovascular, infarto de miocardio, accidente cerebrovascular, hospitalización por angina

Palabras clave:

Enfermedad cardiovascular

Prevención secundaria

Análisis de costes y costes

Anticuerpos monoclonales PCSK9

SEE RELATED CONTENT:

<http://dx.doi.org/10.1016/j.rec.2018.05.044>

* Corresponding author: Escuela Andaluza de Salud Pública, Campus Universitario de Cartuja, Apartado de Correos 2070, 18080 Granada, Spain.

E-mail address: antonio.olrylabry.easp@juntadeandalucia.es (A. Olry de Labry Lima).

<https://doi.org/10.1016/j.rec.2018.05.003>

1885-5857/© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

inestable o revascularización coronaria; segunda: incluye los 3 primeros eventos). A 10 años, el modelo de Markov mostró un coste promedio de 471.417,37 frente a 13.948,45 euros con evolocumab y estándar respectivamente. El tratamiento con evolocumab en hipercolesterolemia familiar supondría anualmente entre 3 y 6,1 millones de euros, lo que supone una diferencia de 2,5-5,1 millones de euros con el tratamiento estándar (2017). Para el año 2021, en hipercolesterolemia no familiar (prevención secundaria), la diferencia osciló entre 204,3 y 1.364,7 millones de euros.

Conclusiones: El evolocumab se asocia con menor frecuencia de eventos cardiovasculares, pero resulta ineficiente para los pacientes susceptibles de recibirlo en el Sistema Nacional de Salud.

© 2018 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Abbreviations

ICER: incremental cost-effectiveness ratio

LDL-C: low-density lipoprotein cholesterol

PCSK9: proprotein convertase subtilisin/kexin type 9

INTRODUCTION

Cardiovascular disease is associated with a high incidence of morbidity and mortality.¹ A major risk factor for cardiovascular events is an individual's atherogenic lipid profile, particularly a high concentration of low-density lipoprotein cholesterol (LDL-C). The standard cholesterol-lowering treatment is statin therapy, but in patients with statin intolerance or a contraindication, large reductions in LDL-C can be achieved with inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9).²

A Cochrane review (2017) including 20 clinical trials and a total of 67 237 participants (median age 61 years; range, 52–64 years) found that PCSK9 inhibitors reduced LDL-C by 53.86% vs placebo (95% confidence interval [95%CI], 58.64–49.08; 4782 participants), by 30.20% vs ezetimibe (95%CI, 34.18–26.23; 823 participants), and by 39.20% vs statins plus ezetimibe (95%CI, 56.15–22.26; 5376 participants).² The studies included in the review had a short-term follow-up (maximum 26 months), and although the studies did not include reductions in cardiovascular events as a main endpoint, the review revealed a modest protective effect (< 1%) with a high level of uncertainty. In March 2017, the first study was published examining cardiovascular morbidity and mortality with the PCSK9 inhibitor evolocumab after a 26-month follow-up.³ Another large morbidity and mortality study is currently evaluating the PCSK9 inhibitor alirocumab.⁴

The European Medicines Agency has approved alirocumab and evolocumab for familial hypercholesterolemia or secondary prevention in dyslipidemia patients in whom statins provide insufficient cholesterol control, due either to refractoriness or to intolerance. These drugs have been commercialized at a much higher price than other cholesterol-lowering drugs, despite the lack of availability of appropriate morbidity and mortality studies.^{5,6} Against a background of limited resources, it is important to increase the efficiency of available treatments. With this goal in mind, the aim of this study was to estimate the cost-effectiveness ratio and budget impact of evolocumab therapy in the Spanish National Health System.

METHODS

We carried out 2 types of economic evaluation: a decision tree (time horizon, 26 months) and a 10-year simulation using a Markov model based on survival-curve analysis.⁷ Both analyses used data from the FOURIER trial,³ and the effectiveness measure was averted cardiovascular events.

Treatment Alternatives

In the FOURIER trial, evolocumab was administered on a background of standard statin therapy according to the patient baseline characteristics.³ Patients received either 420 mg every 4 weeks or 140 mg every 2 weeks; however, we based cost calculations on the biweekly pattern, as this is the regimen presented in the technical data sheet; in the absence of disaggregated data, both dose regimens were assumed to have similar efficacy. In the study, approximately 70% of patients received high-intensity statin therapy and the other 30% moderate-intensity statin therapy. In both situations, approximately 5% of the patients received concomitant ezetimibe therapy. The cost and effectiveness data used are summarized in Table 1.^{3,5,8–11}

Effectiveness Measures

The preferred outcome measure of a cost-effectiveness analysis is quality-adjusted life-years gained. However, the focus of the current analysis was the effectiveness at averting cardiovascular events and the associated treatment costs. The measures used here are the efficacy endpoints considered in the FOURIER trial³: a) primary: the composite of cardiovascular death, myocardial infarction, stroke, hospitalization due to unstable angina, or coronary revascularization, and b) secondary: the composite of cardiovascular death, myocardial infarction, or stroke.

Cost Estimation

Costs were estimated from the perspective of the Spanish National Health System, and therefore indirect costs due to productivity loss were excluded. The costs of events identified in the FOURIER trial³ were estimated according to the Spanish Ministry of Health Diagnostic Related Groups patient classification system, with severity gauged from event incidence in the public health system in Andalusia. The cost of evolocumab therapy was estimated from the unit cost cited in the Spanish prescription medicines registry (*Nomenclátor*) in September 2017. The cost of ezetimibe therapy was obtained from the Spanish College of Pharmacists online BOT resource,⁸ and the cost of statin therapy was obtained from Villa et al.⁹

Budget Impact Analysis

The Spanish Medicines Agency guidelines (*Informe de Posicionamiento Terapéutico*) for evolocumab define treatment-eligible patients as those whose hypercholesterolemia is not controlled by standard therapy (LDL-C not brought to ≤ 100 mg/dL). This criterion applies whether failed statin therapy is due to non-responsiveness to the maximum dose, intolerance, or a contraindication and applies equally to patients with homozygotic or heterozygotic familial hypercholesterolemia and to those with established cardiovascular disease.¹³

The budget impact analysis¹⁴ for patients in secondary prevention^{10,11} was based on prevalence data and projection over a 5-year time horizon (2017–2021) (Table 1). The treatment-eligible population was estimated from data in various registries and reports, and when necessary was extrapolated to the national total.^{15–21} Moreover, the assumption was made that 14% of individuals would not achieve LDL-C reductions to < 100 mg/dL with standard statin therapy, due either to ineffectiveness of the maximum tolerated dose or to intolerance. The sensitivity analysis examined secondary prevention prevalence rates of 0.9% and 6.01% (supplementary material text). For both alternatives, the analysis assumed secondary prevention with evolocumab + statins vs statins or vs statins + ezetimibe (5% of patients) and the event probabilities associated with these treatment alternatives. The

populations (> 18 years) for each of the years analyzed were obtained from Spanish National Institute of Statistics population estimates (2016).²²

Economic Evaluation

Decision trees provide a simplified representation of the choice of the most cost-effective alternative. The results are expressed as the cost per averted cardiovascular event with evolocumab (evolocumab + statins) vs the cost per averted event with standard therapy (statins and statins + ezetimibe), calculated as the incremental cost-effectiveness ratio (ICER) = (cost of alternative B – cost of alternative A) / (efficacy B – efficacy A).

Table 1
Prevalence, Efficacy, and Costs in the Budget Impact and Economic Evaluation Analyses

Model parameters	
Concept	Mean value
Annual cost of drugs, €	
<i>Evolocumab (LP with applicable discount)</i>	4969.74
<i>Ezetimibe</i>	668.33 ⁸
<i>Statins</i>	104.87 ⁹
Cost of cardiovascular events, €	
<i>Cardiovascular death</i>	5014.27
<i>Death due to myocardial infarction</i>	3912.66
<i>Death due to stroke</i>	4994.57
<i>All-cause death</i>	0
<i>Myocardial infarction</i>	3912.66
<i>Hospitalization due to unstable angina</i>	2765.74
<i>Stroke</i>	4994.57
<i>Ischemic</i>	4994.57
<i>Hemorrhagic</i>	5545.22
<i>Coronary revascularization</i>	5924.87
Relative risk^a	
<i>Total follow-up period</i>	
Primary outcome ^b	0.85 (95%CI, 0.79–0.92)
Secondary outcome ^c	0.80 (95%CI, 0.73–0.88)
<i>1-year follow-up</i>	
Primary outcome ^b	0.88 (95%CI, 0.80–0.97)
Secondary outcome ^c	0.84 (95%CI, 0.74–0.96)
Proportion of events in the primary outcome measure, %	
<i>Cardiovascular death</i>	12.94
<i>Myocardial infarction</i>	24.46
<i>Hospitalization due to unstable angina</i>	12.23
<i>Stroke</i>	10.79
<i>Coronary revascularization</i>	39.56
Proportion of events in the secondary outcome measure, %	
<i>Cardiovascular death</i>	26.86
<i>Myocardial infarction</i>	50.74
<i>Stroke</i>	22.38
Uncontrolled patients in secondary prevention, %	
<i>Prevalence in secondary prevention^d</i>	3.5 ¹⁰ ; 0.9; 6.01 (supplementary material text)
<i>Poor lipid control (LDL-C ≥ 100 mg/dL) in secondary prevention</i>	8.0–44.0 ^{5,10,11}
<i>Medication uptake^e</i>	12.4 (year 1); 31.2 (year 2); 87.5 (year 3); 93.7 (year 4); 100 (year 5) ⁵

LDL-C, low-density lipoprotein cholesterol; LP, laboratory price; 95%CI, 95% confidence interval.

^a Data from the FOURIER study,³ including patients in secondary prevention with statin intolerance or an insufficient treatment response.

^b Primary outcome measure: composite of cardiovascular death, myocardial infarction, stroke, hospitalization due to unstable angina, or coronary revascularization.

^c Secondary outcome measure: composite of cardiovascular death, myocardial infarction, or stroke.

^d Estimated prevalence of secondary prevention in the general population.

^e Medication uptake: percentage of patients using the medication and the change in usage over time.

The uncertainty level was evaluated with a univariate sensitivity analysis for a 46% reduction in the price of evolocumab.²³ In addition, a probabilistic sensitivity analysis was carried out in Excel with the frequency of the primary and secondary outcomes (beta probability distribution), allowing evaluation of the parametric uncertainty of the probabilities through 1000 simulations.

Markov Model: Effectiveness and Assumptions

Disease progression was simulated using 2 mutually exclusive health states. All patients were entered in the model in the *progression-free* state and either remained in this state or transitioned to the *new event* state, depending on the transition probabilities. A general proportion of each type of event was assumed in the final computation. In this type of model, transitions between states take place in discrete periods called *cycles*; the current model used a cycle duration of 1 month and a time horizon of 120 months. Following the recommendations of López Bastida et al.,²⁴ the sensitivity analyses were carried out with discounting at rates of 3.5% and 6%. (The discounting rate refers to the fact that costs and outcomes may occur at different times, whereas the comparison is made at a single moment; the discounting rate is thus a rate of adjustment for the passage of time.)

Monthly probabilities were calculated by survival curve modeling. Data points were obtained from digitized survival curves and were used together with the published aggregated survival data to recreate the Kaplan-Meier curves using the algorithm of Guyot et al.²⁵ The generated data were compared with the original data by calculating the Cox regression hazard ratio (HR). Different parametric distributions were analyzed (exponential, lognormal, Weibull, gamma, gamma-generalized, and log-logistic), and we selected the one giving the best fit to Akaike and Bayesian information criteria (Table 1 of the supplementary material). Finally, the Simpson rule was used to calculate the area under the curve (AUC), which represents the mean time that patients were free of events (Table 2 of the supplementary material); $AUC_{0-36 \text{ months}}$ and $AUC_{0-120 \text{ months}}$ were calculated for both treatment branches and for both outcomes analyzed. All calculations were made using the Flexsurv package in the R statistical program.²⁶

RESULTS

Cost-Effectiveness Analysis: Decision Tree

The results at 26 months showed that patients treated with evolocumab had event rates for the primary and secondary efficacy endpoints of 9.8% and 5.9%, respectively, compared with 11.3% and 7.4% for patients receiving standard therapy. The mean base-case per-patient cost of evolocumab therapy was €11 134.78 for the primary outcome and €11 088.46 for the secondary outcome; the corresponding costs for patients receiving standard therapy were €393.83 and €328.15, respectively. In the base-case analysis, the ICER (the additional cost per averted cardiovascular event or death) was €633 684.39 for the primary outcome and €717 354.20 for the secondary outcome. Sensitivity analysis for a 46% reduction in the price of evolocumab yielded corresponding ICER values of €341 795.91 and €387 520.21. In the probabilistic analysis, the ICER was €716 857.98 for the primary outcome and €776 333.52 for the secondary outcome (Table 2).

Markov Model

For the primary outcome measure, the HR obtained in the cohort simulation was similar to that reported in the trial (HR = 0.85;

95%CI, 0.79-0.91). In the survival curve modeling (Figure 1 of the supplementary material and Figure 2 of the supplementary material), the lognormal distribution gave the best fit for both treatment branches (Table 1 of the supplementary material). The HR obtained in the cohort simulation for the second outcome was also similar to the trial value (HR = 0.80; 95%CI, 0.73-0.87). Once the survival curves were defined, the 120-month cumulative incidence was calculated. For the primary outcome measure, the cumulative incidences for the evolocumab and standard therapy groups were 0.263 (95%CI, 0.251-0.279) and 0.313 (95%CI, 0.298-0.330), respectively; for the secondary outcome, the values were 0.168 (95%CI, 0.156-0.182) and 0.216 (95%CI, 0.202-0.232).

The Markov model analysis for the 10-year horizon is shown in Table 3. For the primary outcome, the projected mean cost of standard therapy with no discounting rate applied was €13 948.45, contrasting with €471 417.37 for evolocumab. This translates into a 10-year ICER of €1 531 434.19, which represents the projected cost of averting 1 additional cardiovascular event upon switching from standard therapy to evolocumab. Application of the 3.5% and 6% discounting rates produced ICER values of €3 101 123.88 and €4 896 643.93, respectively. For the secondary outcome, the switch from standard therapy to evolocumab incurred an additional cost of €2 171 421.91 for each averted event with no discounting. Applying the 3.5% and 6% discounting rates increased this cost to €4 090 566.86 and €6 177 284.00, respectively.

Budget Impact

The budget impact was analyzed by comparing evolocumab therapy (evolocumab + statins) with standard therapy (statins + ezetimibe) for a range of scenarios in 2017. The first scenario considered a population of 100 000 patients with familial hypercholesterolemia, a detection rate of 15%, and rates of poor lipid control between 50% and 100%. In these scenarios, the cost of evolocumab therapy would range between €3 million and €6 million, corresponding to €2.5 million and €5.1 million more than the cost of standard therapy. In the other scenarios examined, the cost difference between evolocumab and standard therapy ranged from €4.2 million to €44.5 million (Table 4).

According to the assumptions considered, the budget impact analysis predicted that 7516 treatment-eligible patients with uncontrolled hypercholesterolemia would be receiving evolocumab therapy in 2017. By 2021, this number would be as high as 60 417 patients, depending on the rate of uptake. For 2021, and depending on the assumptions made, the projected cost difference between evolocumab and standard therapy would range from €116 785 548.70 to €779 867 941.88 (Table 5).

DISCUSSION

Evolocumab therapy is associated with a lower frequency of events; however, according to the results of the present study, its use is inefficient in the Spanish National Health System. The cost-effectiveness models presented here reveal an ICER of €650 000 for each cardiovascular event averted with evolocumab compared with the standard therapy. Given the lack of a cost threshold for evaluating this type of result, it is difficult to reach a firm conclusion about the cost-effectiveness of evolocumab therapy.

Limitations

A limitation of the present study is the varying level of rigor in the Diagnostic Related Groups patient classification system for calculating complications.¹² The data reported here may not reflect the situation in Spain; however, any discrepancy is likely to be

Table 2
Incremental Cost-effectiveness of Evolocumab Versus Standard Therapy: Base-Case and Sensitivity Analysis Over a 26-month Time Horizon

Treatment alternative	Cost, €	Incremental cost, €	Effectiveness ^a	Incremental effectiveness ^b	ICER, €/averted event ^c
<i>Base case. Primary outcome^d</i>					
Standard therapy	393.83		0.887		
Evolocumab	11 134.78	10 740.95	0.904	0.017	633 684.39
<i>Base case. Secondary outcome^e</i>					
Standard therapy	328.15		0.926		
Evolocumab	11 088.46	10 760.31	0.941	0.015	717 354.20
<i>Univariate sensitivity analysis for a 46% reduction in the cost of evolocumab. Primary outcome^d</i>					
Standard therapy	393.83		0.887		
Evolocumab	6187.27	5793.44	0.904	0.017	341 795.91
<i>Univariate sensitivity analysis for a 46% reduction in the cost of evolocumab. Secondary outcome^e</i>					
Standard therapy	328.15		0.926		
Evolocumab	6140.95	5 812.80	0.941	0.015	387 520.21
<i>Probabilistic sensitivity analysis. Primary outcome^d</i>					
Standard therapy	394.13 (389.68-398.64)		0.887 (0.881-0.892)		
Evolocumab	11 135.74 (11 132.57-11 139.02)	10 741.60	0.902 (0.898-0.907)	0.016	716 857.98
<i>Probabilistic sensitivity analysis. Secondary outcome^e</i>					
Standard therapy	327.99 (326.58-329.49)		0.926 (0.922-0.931)		
Evolocumab	11 088.48 (11 087.47-11 089.47)	10 760.49	0.941 (0.937-0.944)	0.014	776 333.52

ICER, incremental cost-effectiveness ratio.

For the probabilistic sensitivity analysis, hundreds of simulations were conducted with random variation of parameters according to their probability distribution.

^a Proportion of patients with no cardiovascular events.

^b Difference in effectiveness between treatment alternatives.

^c ICER represents the additional cost in euros per averted cardiovascular event or death.

^d Primary outcome measure: composite of cardiovascular death, myocardial infarction, stroke, hospitalization due to unstable angina, or coronary revascularization.

^e Secondary outcome measure: composite of cardiovascular death, myocardial infarction, or stroke.

Table 3
Markov Model of Evolocumab Versus Standard Therapy, With or Without a Discounting Rate Over a 10-year Time Horizon

Treatment alternatives	Cost, €	Incremental cost, €	Mean event-free period, years	Incremental effectiveness, years ^a	ICER, €/averted event ^b
10-year projection					
<i>Primary outcome^c</i>					
Standard therapy	13 948.45		8.08		
Evolocumab	471 417.37	457 469.25	8.38	0.30	1 531 434.19
<i>Primary outcome^c (discounting rate = 3.5%)</i>					
Standard therapy	3344.46		2.13		
Evolocumab	112 180.93	108 836.47	2.17	0.04	3 101 123.88
<i>Primary outcome^c (discounting rate = 6%)</i>					
Standard therapy	2008.57		1.32		
Evolocumab	67 177.76	65 169.19	1.34	0.01	4 896 643.93
<i>Secondary outcome^d</i>					
Standard therapy	13 769.74		8.71		
Evolocumab	471 296.71	457 526.97	8.92	0.21	2 171 421.91
<i>Secondary outcome^d (discounting rate = 3.5%)</i>					
Standard therapy	3282.64		2.22		
Evolocumab	112 137.63	108 854.99	2.24	0.03	4 090 566.86
<i>Secondary outcome^d (discounting rate = 6%)</i>					
Standard therapy	1967.08		1.36		
Evolocumab	67 148.19	65 181.10	1.37	0.01	6 177 284.00

ICER, incremental cost-effectiveness ratio.

Annual discounting rate for costs and outcomes to adjust for the passage of time.

^a Difference in effectiveness between alternative treatments.

^b ICER represents the additional cost in euros per averted cardiovascular event or death.

^c Primary outcome measure: composite of cardiovascular death, myocardial infarction, stroke, hospitalization due to unstable angina, or coronary revascularization.

^d Secondary outcome measure: composite of cardiovascular death, myocardial infarction, or stroke.

Table 4
Annual Treatment Costs For Familial Hypercholesterolemia Patients in Different Scenarios (2017)

Poor lipid control	Population	Cost of evolocumab, €	Cost of standard therapy, € ^a	Difference, €
<i>No. familial hypercholesterolemia patients, 100 000; detection rate, 15%^b; statin intolerance, 8%; analysis according to different rates of poor lipid control</i>				
50%	600	3 065 096.08	492 155.54	2 572 940.54
71.5%	858	4 383 087.39	703 782.42	3 679 304.97
88.8%	1066	5 443 610.64	874 068.24	4 569 542.39
96.6%	1159	5 921 765.62	950 844.51	4 970 921.12
100%	1200	6 130 192.16	984 311.08	5 145 881.08
<i>No. familial hypercholesterolemia patients, 100 000; detection rate, 25%; statin intolerance, 8%; analysis according to different rates of poor lipid control</i>				
50%	1000	5 108 493.47	820 259.24	4 288 234.23
71.5%	1430	7 305 145.65	1 172 970.71	6 132 174.95
88.8%	1776	9 072 684.39	1 456 780.40	7 615 903.99
96.6%	1932	9 869 609.37	1 584 740.84	8 284 868.53
100%	2000	10 216 986.93	1 640 518.47	8 576 468.46
<i>No. familial hypercholesterolemia patients, No. = 100 000; detection rate, 40%; statin intolerance, 8%; analysis according to different rates of poor lipid control</i>				
50%	1600	8 173 589.54	1 312 414.78	6 861 174.77
71.5%	2288	11 688 233.05	1 876 753.13	9 811 479.92
88.8%	2842	14 516 295.03	2 330 848.64	12 185 446.39
96.6%	3091	15 791 375.00	2 535 585.35	13 255 789.65
100%	3200	16 347 179.09	2 624 829.55	13 722 349.53
<i>No. familial hypercholesterolemia patients, 130 000; detection rate, 100%; statin intolerance, 8%; analysis according to different rates of poor lipid control</i>				
50%	5200	26 564 166.02	4 265 348.03	22 298 817.99
71.5%	7436	37 986 757.41	6 099 447.68	31 887 309.73
88.8%	9235	47 177 958.85	7 575 258.09	39 602 700.76
96.6%	10 046	51 321 968.75	8 240 652.38	43 081 316.36
100%	10 400	53 128 332.04	8 530 696.05	44 597 635.99

The model assumes that 8% of familial hypercholesterolemia patients (homozygotic or heterozygotic) are statin intolerant. Possible rates of poor lipid control are taken from the literature.^{10,11,14} Estimates are presented for different levels of uncertainty.

^a Includes the costs of statins, ezetimibe, and complications.

^b Percentage of patients detected, diagnosed, and eligible for treatment.

small. The analysis did not consider mid- and long-term costs due to complications. The survival curve modeling allowed us to project costs over a 10-year time horizon; however, it is important to recognize that the recorded data cover a follow-up of just 26 months and that there is therefore high uncertainty in the model. Because of this, there were insufficient data to model all the events considered, and an estimate of cost per quality-adjusted life-year gained would have required overly risky assumptions. We felt it important to respect this limitation rather than present cost-effectiveness data purporting to support decision making. Finally, given the lack of endpoint studies for the familial hypercholesterolemia patients, primary prevention costs and budget impact for these patients were calculated from the efficacy data for dyslipidemia patients in secondary prevention.

The FOURIER study includes a population with only moderately high mean LDL-C values at baseline (92 mg/mL).³ However, the analysis showed no correlation between cardiovascular protection and the severity of baseline cholesterolemia; there was no significant difference between the protective effect for patients with LDL-C < 80 mg/dL (HR = 0.80; 95%CI, 0.69–0.93) and those with LDL-C > 109 mg/dL (HR = 0.89; 95%CI, 0.77–1.02).

Several long-term cost-utility analyses have evaluated the ability of PCSK9 inhibitors to improve the lipid profiles of US patients in long-term models. Although these studies are highly heterogeneous, they all report high ICER values, between 268 637 and 506 000 dollars per quality-adjusted life-year gained.^{27–29} In contrast, a Spanish study by Villa et al. reported ICER values between €30 893 and €42 266 per quality-adjusted life-year gained.⁹ The difference between these reported values may be due to the price of evolocumab, which was \$14 000 to \$14 600 per patient per year

in the US-based studies,^{27–29} whereas the cost used in the study by Villa et al.⁹ was \$4969.60 per patient per year. Moreover, the estimated cardiovascular mortality reductions in that study were based on extrapolations from LDL-C values and were much larger than the reductions reported in the FOURIER study; had the analysis been based on the FOURIER trial data, the efficiency of evolocumab would also have been lower.

Another 2 recent reports evaluated the cost-effectiveness of evolocumab from the US health system perspective, using clinical data from the FOURIER study; these studies generated ICER values of \$37 729 and 450 000 dollars per quality-adjusted life-year gained.^{30,31}

The reduction in morbidity and mortality was not as expected, for complex reasons that as yet remain unclear.²⁸ Cardiovascular events have a multitude of causes, and pharmacological agents also have multiple effects. Reductions in cholesterol, blood pressure, and blood glucose show a clear epidemiological association with reductions in major adverse cardiovascular events; however, this association does not necessarily hold for all mechanisms of action or clinical situations,³² as for example demonstrated for metformin monotherapy vs its administration in combination with sulfonylureas in type 2 diabetes patients.³³ It is therefore essential that results be confirmed in clinical endpoint studies.³⁴ Clinical situations involving significant injury and high risk can occur in the context of only moderately elevated LDL-C, as seen among patients in the FOURIER trial; these patients may therefore be less responsive to lipid-lowering therapies than those with lower disease severity but less pronounced dyslipidemia. It should be noted that the percentage reduction in LDL-C achieved by the addition of a drug to a pre-existing therapy will be less than that achieved with the same drug given as monotherapy at baseline.³⁵

Table 5

Treatment Costs for Treatment-eligible Secondary Prevention Patients With Uncontrolled Hypercholesterolemia

Year	Population ^a	Evolocumab cost, €	Statin cost, €	Difference, €
<i>Assuming progressive medication uptake^c</i>				
2017	7516	38 395 295.69	6 165 045.74	32 230 249.95
2018	18 808	96 078 750.29	15 427 147.52	80 651 602.77
2019	52 737	269 409 059.05	43 258 402.96	226 150 656.08
2020	56 561	288 941 084.55	46 394 616.10	242 546 468.46
2021	60 417	308 639 780.59	49 557 591.14	259 082 189.44
<i>100% medication uptake^c</i>				
2017	60 183	307 442 623.15	49 365 366.28	258 077 256.86
2018	60 210	307 582 847.46	49 387 881.78	258 194 965.68
2019	60 264	307 855 976.85	49 431 737.55	258 424 239.30
2020	60 338	308 235 043.52	49 492 603.43	258 742 440.09
2021	60 417	308 639 780.59	49 557 591.14	259 082 189.44
<i>Secondary prevention 6.01%^b and progressive medication uptake^c</i>				
2017	22 624	115 574 367.70	18 557 514.69	97 016 853.01
2018	56 613	289 208 368.22	46 437 533.23	242 770 834.99
2019	158 746	810 953 037.16	130 212 894.06	680 740 143.10
2020	170 255	869 746 737.20	139 653 265.43	730 093 471.77
2021	181 862	929 042 135.19	149 174 193.31	779 867 941.88
<i>Secondary prevention 6.01%^b and 100% medication uptake^c</i>				
2017	181 157	925 438 550.12	148 595 573.81	776 842 976.31
2018	181 239	925 860 641.84	148 663 348.12	777 197 293.72
2019	181 400	926 682 793.50	148 795 359.15	777 887 434.35
2020	181 624	927 823 828.89	148 978 572.62	778 845 256.27
2021	181 862	929 042 135.19	149 174 193.31	779 867 941.88
<i>Secondary prevention 0.9%^b and progressive medication uptake^c</i>				
2017	3388	17 307 309.64	2 778 995.54	14 528 314.10
2018	8478	43 309 073.44	6 954 039.92	36 355 033.53
2019	23 772	121 440 554.65	19 499 435.05	101 941 119.60
2020	25 496	130 244 935.69	20 913 134.59	109 331 801.10
2021	27 234	139 124 446.20	22 338 897.50	116 785 548.70
<i>Secondary prevention 0.9%^b and 100% medication uptake</i>				
2017	27 128	138 584 807.84	22 252 248.99	116 332 558.85
2018	27 141	138 648 016.25	22 262 398.22	116 385 618.03
2019	27 165	138 771 133.80	22 282 166.93	116 488 966.87
2020	27 198	138 942 004.33	22 309 603.22	116 632 401.11
2021	27 234	139 124 446.20	22 338 897.50	116 785 548.70

The model assumes that 14% of patients have poor lipid control despite optimized statin therapy; this figure includes an estimated 8% of patients with statin intolerance. The mean per-patient cost is €5511.30 for evolocumab + statin therapy and €820.26 for ezetimibe + statins.

^a Population: estimated number of treatment-eligible patients according to the assumptions.

^b Estimated rate of secondary prevention in the general population.

^c Medication uptake: percentage of patients using the medication and the change in usage over time; 100% uptake: the entire population is assumed to receive the medication from the outset.

For some drugs and clinical situations, it is possible that consensus goals for LDL-C lowering based on expert assessment of epidemiological data will not produce the hoped for clinical outcomes.

These results highlight the advisability of major price reductions for PCSK9 inhibitors.^{27,28,30,31,36} This would improve efficiency and reduce the budget impact. The maintenance of the current high prices for these treatments places great importance on patient selection.³⁶ Spanish public funding criteria for PCSK9 inhibitors (released before the availability of morbidity and mortality data) include LDL-C > 100 mg/dL.^{37,38} The Spanish Society of Atherosclerosis and other organizations such as the UK NICE (National Institute for Health and Care Excellence) propose a progressive scale of LDL-C values for PCSK9 inhibitor initiation, with the threshold depending on the attributable risk in specific

patient subgroups.^{39–42} It would be useful to have a more detailed analysis of economic and organizational factors related to PCSK9 inhibitor use, including a budget impact analysis to identify the most efficient strategy.

In any event, it is also highly recommendable to achieve the best possible lipid control before introducing PCSK9 inhibitor therapy.⁴³ Advisable steps include reviewing treatment adherence, maximizing statin therapy effectiveness through careful drug and dose selection, improving strategies to increase tolerance, and using other available treatments such as ezetimibe. All patients placed on PCSK9 inhibitor therapy should be monitored closely, and strategies should be investigated to refine the treatment regimen as required.⁴⁴

An examination of the subgroup analysis in the FOURIER study suggests that the number of averted cardiovascular events may be

lower in Europe (HR = 0.91; 95%CI, 0.83–1.00) than in North America (HR = 0.77; 95%CI, 0.66–0.90).³ More detailed knowledge would be useful about factors affecting possible effect differences related to comorbidities and other risk factors, such as diabetes. Publication of the results of the ODYSSEY trial with alirocumab will provide additional information about the cardiovascular benefits of PCSK9 inhibitors.⁴

CONCLUSIONS

The present study increases the information available on the efficiency of PCSK9-inhibitor therapy and its usefulness and projected impact in the Spanish National Health System. The analysis presented here indicates that evolocumab therapy is currently not cost-effective in patients at high cardiovascular risk and LDL-C > 100 mg/dL. In light of these findings, a major price review of PCSK9 inhibitors is warranted.

CONFLICTS OF INTEREST

None declared.

WHAT IS KNOWN ABOUT THE TOPIC?

- Major clinical trials with PCSK9 inhibitors have shown large reductions in LDL-C. The price of these drugs was established before the availability of morbidity and mortality data, and is considerably higher than for other drugs used in cardiovascular prevention.
- In a clinical trial of evolocumab vs placebo in secondary prevention, a cardiovascular event was averted in 1.5% of patients (9.8% vs 11.3%) after 26 months.

WHAT DOES THIS STUDY ADD?

- For the Spanish National Health System, the ICER for evolocumab at the current price was €600 000 per averted cardiovascular event at 6 months.
- The budget impact of introducing evolocumab for secondary prevention in Spain (2017) for patients with LDL-C > 100 mg/dL would be between €32 million and €259 million.

SUPPLEMENTARY MATERIAL



Supplementary material associated with this article can be found in the online version available at [doi:10.1016/j.rec.2018.05.003](https://doi.org/10.1016/j.rec.2018.05.003).

REFERENCES

1. OMS: Organización Mundial de la Salud. Informe sobre la situación mundial de las enfermedades no transmisibles 2010. Available at: http://www.who.int/nmh/publications/ncd_report2010/es/. Accessed 2 Oct 2017.
2. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2017;4:CD011748.
3. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wiviott SM. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1–10.
4. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of alirocumab on the occurrence of cardiovascular events in patients who have recently experienced an acute coronary syndrome. Available at: <https://clinicaltrials.gov/ct2/show/NCT01663402>. Accessed 29 Aug 2017.
5. National Institute for Health and Care Excellence. Putting NICE guidance into practice. Resource impact report: Alirocumab (TA393) and evolocumab (TA394) for treating primary hypercholesterolaemia and mixed dyslipidaemia. National Institute for Health and Care Excellence. 2016. Available at: <https://www.nice.org.uk/guidance/ta394/resources/resource-impact-report-pdf-2543362381>. Accessed 2 Aug 2017.
6. National Institute for Health and Care Excellence. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Available at: <https://www.nice.org.uk/guidance/ta394>. Accessed 2 Aug 2017.
7. Mar J, Antoñanzas F, Pradas R, Arrospide A. Los modelos de Markov probabilísticos en la evaluación de tecnologías sanitarias: una guía práctica. *Gac Sanit*. 2010;24:209–214.
8. Bot Plus 2.0. Consejo General de Colegios Oficiales de Farmacéuticos. <https://botplusweb.portalafarma.com/botplus.aspx>. Accessed 8 Sep 2017.
9. Villa G, Lothgren M, Kutikova L, et al. Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain. *Clin Ther*. 2017;39:771–786.
10. De la Sierra A, Pintó X, Guisjarro C, et al. Prevalence, treatment, and control of hypercholesterolemia in high cardiovascular risk patients: evidences from a systematic literature review in Spain. *Adv Ther*. 2015;32:944–961.
11. Lázaro P, Pérez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. *J Clin Lipidol*. 2017;11:260–271.
12. Ministerio de Sanidad, Servicios Sociales e Igualdad. Costes hospitalarios-Contabilidad Analítica. Available at: <https://www.msssi.gob.es/estadEstudios/estadisticas/inforRecopilaciones/anaDesarrolloGDR.htm>. Accessed 29 Jul 2017.
13. Mata P, Alonso R, Ruiz A, et al. Diagnóstico y tratamiento de la hipercolesterolemia familiar en España: documento de consenso. *Aten Primaria*. 2015;47:56–65.
14. Brosa M, Gisbert R, Rodríguez JM, Soto J. Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario. *PharmacoEconomics Spanish Research Articles*. 2005;2:65–78.
15. Brea A, Laclaustra M, Martorell E, Pedragosa A. Epidemiología de la enfermedad vascular cerebral en España. *Clin Invest Arterioscl*. 2013;25:211–217.
16. Muñoz MA, Marrugat J. La prevención secundaria de la enfermedad coronaria es menos agresiva en los pacientes de más de 64 años. *Rev Esp Cardiol*. 2003;56:586–593.
17. Félix-Redondo FJ, Fernández-Bergés D, Grau M, Baena-Diez JM, Mostaza JM, Vila J. Prevalencia y características clínicas de la enfermedad arterial periférica en la población general del estudio Hermex. *Rev Esp Cardiol*. 2012;65:726–733.
18. Marrugat J, Elosua R, Grau M, Sayols-Baixeras S, Dégano IR. Prevalencia y pronóstico de los pacientes con infarto de miocardio de alto riesgo candidatos a doble tratamiento antiagregante prolongado. *Rev Esp Cardiol*. 2016;69:480–487.
19. Alonso JJ, Muñoz J, Gómez-Doblas JJ, et al. Prevalencia de angina estable en España. Resultados del estudio OFRECE. *Rev Esp Cardiol*. 2015;68:691–699.
20. Ramos R, Quesada M, Solanas P, et al. REGICOR Investigators. Prevalence of symptomatic and asymptomatic peripheral arterial disease and the value of the ankle-brachial index to stratify cardiovascular risk. *Eur J Vasc Endovasc Surg*. 2009;38:305–311.
21. Bonet Basiero A, Bardají A. Epidemiología de la angina estable. *Rev Esp Cardiol Supl*. 2010;10(B):3–10.
22. Instituto Nacional de Estadística. Proyecciones de población a corto plazo. Available at: <http://www.ine.es/jaxi/menu.do?type=pcaxis&path=/t20/p269&file=inebase>. Accessed 8 Jun 2017.
23. Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. *Boletín Oficial del Estado*, 24 de mayo de 2010. Available at: <https://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf>. Accessed 8 Sep 2017.
24. López Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. *Gac Sanit*. 2010;24:154–170.
25. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res Methodol*. 2012;12:9.
26. Jackson C. Flexsurv: Flexible parametric survival and multi-state models. 2014. Available at: <https://cran.r-project.org/>. Accessed 28 Sep 2017.
27. Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. *JAMA Cardiol*. 2017;2:1069–1078.
28. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. *JAMA*. 2016;316:743–753.
29. Shah P, Glueck CJ, Jetty V, et al. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center. *Lipids Health Dis*. 2016;15:1–9.
30. Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. *JAMA Cardiol*. 2017;2:1369–1374.
31. Kazi DS, Penko J, Coxson PG, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. *JAMA*. 2017;318:748–750.
32. Lasagna L. Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *JAMA*. 2000;283:2013–2014.
33. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type2 diabetes mellitus. *Metabolism*. 2004;53:159–164.
34. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. *Am Fam Physician*. 2004;69:548–556.

35. Masana I, Ibarretxe D, Plana N. Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60. *Rev Esp Cardiol*. 2016;69:342–343.
36. Hadjiphilippou S, Ray KK. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? *Heart*. 2017;103:1670–1679.
37. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de Posicionamiento Terapéutico de evolocumab (Repatha®) en hipercolesterolemia 2016. Available at: <https://www.aemps.gob.es/en/medicamentosUsoHumano/informesPublicos/docs/IPT-evolocumab-repatha.pdf>. Accessed 1 Jun 2017.
38. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de Posicionamiento Terapéutico de alirocumab (Praluent®) en hipercolesterolemia 2016. Available at: <https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-alirocumab-Praluent-hipercolesterolemia.pdf>. Accessed 1 Jun 2017.
39. Masana L, Ascaso JF, Civeira F, et al. Documento de consenso de la Sociedad Española de Arteriosclerosis sobre las indicaciones de los inhibidores de la PCSK9. *Clin Invest Arterioscl*. 2016;28:164–165.
40. Carroll C, Tappenden P, Raha R, et al. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal. *Pharmacoeconomics*. 2017;35:537–547.
41. National Institute for Health and Care Excellence. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Available at: <https://www.nice.org.uk/guidance/ta393>. Accessed 2 Aug 2017.
42. Masana L, Civeira F, Pedro-Botet J, et al. Consenso de expertos sobre la detección y el manejo clínico de la hipercolesterolemia familiar. *Clin Invest Arterioscl*. 2013;25:182–193.
43. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? *Curr Atheroscler Rep*. 2013;15:291.
44. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. *Br J Clin Pharmacol*. 2014;78:684–698.